



**PRESS RELEASE**

30 October 2024 13:00:00 CET

## Invitation to presentation of Senzime's third quarter 2024 report

Senzime invites investors, analysts, and media to a webcast presentation of the third quarter report for 2024 on November 6, 15:00 CET. The report will be published during the morning of the same day.

The presentation will be held by Philip Siberg, CEO of Senzime, and after the presentation, there will be a Q&A session moderated by Klas Palin, analyst at Carnegie Investment Bank. The presentation will be held in English.

Date and time: Wednesday, November 6, 15:00-15:30 CET

Questions to moderator can be sent by email in advance to [klas.palin@carnegie.se](mailto:klas.palin@carnegie.se) before 12:00 CET on Nov 6.

The presentation will be accessible at Senzime's website <https://www.senzime.com/investors>

**For further information, please contact:**

---

Philip Siberg, CEO of Senzime AB  
Phone: +46 (0) 707 90 67 34, e-mail: [philip.siberg@senzime.com](mailto:philip.siberg@senzime.com)

Slavoljub Grujcic, CFO  
Phone: +46 (0) 76 306 60 11, e-mail: [slavoljub.grujcic@senzime.com](mailto:slavoljub.grujcic@senzime.com)

### About Senzime

---

Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany.

Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at [senzime.com](https://www.senzime.com).

## Attachments

---

Invitation to presentation of Sensime's third quarter 2024 report